Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Profit After Tax: 2015-2025

Historic Profit After Tax for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $8.2 million.

  • Seres Therapeutics' Profit After Tax fell 90.76% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 128.47%. This contributed to the annual value of -$125.8 million for FY2024, which is 33.85% up from last year.
  • As of Q3 2025, Seres Therapeutics' Profit After Tax stood at $8.2 million, which was up 141.32% from -$19.9 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Profit After Tax high stood at $88.8 million for Q3 2024, and its period low was -$71.2 million during Q1 2023.
  • In the last 3 years, Seres Therapeutics' Profit After Tax had a median value of -$19.9 million in 2025 and averaged -$7.8 million.
  • As far as peak fluctuations go, Seres Therapeutics' Profit After Tax skyrocketed by 325.29% in 2021, and later slumped by 187.96% in 2022.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Profit After Tax stood at -$50.0 million in 2021, then plummeted by 37.59% to -$68.8 million in 2022, then spiked by 49.54% to -$34.7 million in 2023, then spiked by 54.96% to -$15.6 million in 2024, then tumbled by 90.76% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, -$19.9 million for Q2 2025, and $32.7 million during Q1 2025.